[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of L'Aquila\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,78,102,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100617119","cardiological-interventions-and-acute-stroke-treatment-study-100617119",false,"NCT07314476","CardioLogical Interventions and Acute strOke Treatment sTudy","CLOT","Inclusion Criteria:\n\n* acute ischemic stroke in adult patient (18 years of age or older) as diagnosed according to the World Health Organization (WHO) criteria;\n* stroke with evidence of CT\u002FMRI DWI\u002FFLAIR acute lesion in the first neuroimaging or in the follow-up at 24-48 h;\n* interventional cardiological procedures performed within 28 days since the stroke onset (Percutaneuous Coronary Intervention - PCI, Transcatheter Aortic Valve Replacement - TAVR, Baloon Aortic Valvuloplasy - BAV, Percutaneous Mitral Valve Repair or Replacement, Patent Formaen Ovale - PFO - or Atrial Septal Defects - ASD - Closure, Left Atrial Appendage Closure, Transcatheter Pulmonary Valve Replacement, Percutaneous Closure of Paravalvular Leaks);\n* written informed consent provided by the patient himself or by proxy (for unconscious patients, cognitively impaired, or aphasic).\n\nExclusion Criteria:\n\n* Stroke-like symptoms due primarily to another non-ischemic\u002Fhemorrhagic acute neurological condition or stroke mimics (e.g. severe hypo- or hyperglycemia, migraine with aura, functional disorders, etc);\n* Spontaneous and post traumatic hemorrhagic stroke or spontaneous\u002Fpost-traumatic subarachnoid hemorrhage or subdural hematoma;\n* AciuImpossibility to achieve written informed consent","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","180 Days","OBSERVATIONAL","The study aims to investigate characteristics and prognosis of ischemic stroke cases following cardiological interventions, focusing on the effectiveness and safety of acute ischemic stroke treatments.",[25,26,27,28,29,30,31,32,33],"Acute Ischemic Stroke AIS","Stroke Treatment","PCI Patients","Aortic Valve Replacement","Transcatheter Aortic Valve Replacement (TAVR)","Mitral Valve Repair","Mitral Valve Replacement","Left Atrial Appendage Closure","Transcatheter Pulmonary Valve Replacement (TPVR)",[35,36,37],"acute ischemic stroke","acute ischemic stroke treatments","cardiological intervention","NOT_YET_RECRUITING","2026-01-04",{"date":41,"type":42},"2026-01-07","ACTUAL",{"date":44,"type":20},"2026-01",{"date":46,"type":20},"2028-12",{"name":48,"class":49},"University of L'Aquila","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100556506","telecoached-exercise-intervention-for-connectivity-enhancement-in-small-vessel-disease-teleconnect-svd-100556506","NCT06525987","Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD)","Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD): a Randomized Clinical Trial","TELECONNECT","Inclusion Criteria:\n\n* Age ≥60 years;\n* History of lacunar stroke occurred between 3 months and 10 years from screening and confirmed by neuroimaging or clinical data by an expert stroke physician;\n* Modified Rankin Scale (mRS) score of 0-1, indicating no symptoms or no significant disability;\n* A level of physical activity below recommended targets, i.e. \\\u003C150 minutes per week of moderate-to-vigorous exercise (24);\n* Ability to sign informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension;\n* Heart disease impairing the possibility of safely following an exercise protocol at the discretion of the treating physician;\n* Primary or secondary epilepsy;\n* Prostheses, implants, and any device that might impair the performance of either high-density electroencephalogram or the exercise intervention;\n* Cognitive impairment (Mini Mental State Examination score ≤26 at follow-up);\n* Lack of access to Internet-based facilities or poor technological alphabetization impairing the adherence to the trial protocol;\n* Any major physical or psychiatric comorbidity that in the judgement of the treating physician might compromise the ability to undergo an exercise intervention.","60 Years",{"count":61,"type":20},60,"INTERVENTIONAL",[64],"NA","The TELECONNECT-SVD study is a prospective, randomized, multicenter trial aimed at testing the efficacy of a remotely delivered exercise protocol on brain functional connectivity in patients with small vessel disease (SVD)-related ischemic stroke. The study will recruit patients aged ≥60 with a history of lacunar stroke, minimal disability (modified Rankin Scale score 0-1), and low physical activity levels.\n\nThe trial will include 60 participants randomized 1:1 to either a 24-week telecoached exercise intervention or usual care. The exercise program consists of multicomponent physical exercises delivered remotely twice a week. Assessments will be conducted at baseline, 12 weeks, 24 weeks, and 48 weeks.\n\nPrimary outcomes include changes in brain functional connectivity assessed by high-density EEG and improvements in physical fitness measured by the Senior Fitness Test. Secondary outcomes encompass changes in physical activity levels, anthropometric measurements, and vital signs.\n\nThe study employs a \"wait list\" design, where the control group receives the intervention after the initial 24-week period. This approach allows for assessment of the intervention's immediate effects and the retention of benefits after cessation.\n\nKey features of the protocol include:\n\n* Use of telecoaching to enhance adherence to the exercise program\n* Comprehensive assessment of brain connectivity using advanced EEG analysis techniques\n* Focus on patients with SVD, who may benefit significantly from exercise interventions\n* Evaluation of both neurophysiological and clinical outcomes\n\nThe study aims to provide evidence for the potential benefits of exercise in enhancing brain connectivity and physical fitness in SVD patients, potentially informing future treatment guidelines and preventive strategies for this population.",[67,68],"Lacunar Stroke","Small Vessel Cerebrovascular Disease","RECRUITING","2025-11-24",{"date":72,"type":42},"2025-12-02",{"date":74,"type":42},"2025-05-02",{"date":76,"type":20},"2026-12-31",{"name":48,"class":49},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":62,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100589781","adjunctive-effect-of-erythritol-on-pocket-closure-rates-100589781","NCT06958874","Adjunctive Effect of Erythritol on Pocket Closure Rates","Adjunctive Effect of Erythritol on Pocket Closure Rates: RCT","Inclusion Criteria:\n\nAdults aged 18 years or older\n\nDiagnosed with stage 3 or 4 periodontitis according to the 2017 classification\n\nPresence of at least 12 natural teeth\n\nPresence of periodontal pockets with probing depth ≥ 4 mm in non-adjacent teeth\n\nGood general health or stable systemic conditions (e.g., controlled diabetes)\n\nExclusion Criteria:\n\nUse of antibiotics or anti-inflammatory drugs within 3 months prior to treatment\n\nPeriodontal treatment in the previous 6 months\n\nPregnancy or breastfeeding\n\nCurrent smokers of more than 10 cigarettes per day\n\nAllergies or intolerance to erythritol or any materials used in the treatment\n\nSystemic diseases or conditions that could influence periodontal healing (e.g., uncontrolled diabetes, immunodeficiency)\n\nUse of medications known to affect periodontal tissues (e.g., phenytoin, cyclosporine, calcium channel blockers)","35 Years",{"count":87,"type":20},56,[64],"This clinical trial is studying whether using erythritol powder during non-surgical periodontal treatment (deep cleaning) helps improve gum health in people with severe periodontitis. Participants with deep gum pockets (4 mm or more) receive standard treatment alone or standard treatment plus cleaning with erythritol powder. The goal is to evaluate if adding erythritol improves outcomes such as healing of gum pockets, bleeding, plaque levels, and gum attachment compared to standard treatment alone.",[91,92,93],"Periodontitis","Pocket, Periodontal","Pocket, Gingival","2025-04-25",{"date":96,"type":42},"2025-05-06",{"date":98,"type":42},"2024-11-08",{"date":100,"type":20},"2025-12-31",{"name":48,"class":49},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":120,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100579374","advancing-knowledge-in-ischemic-stroke-patients-on-oral-anticoagulants-100579374","NCT06823466","Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants","Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants - The ASPERA International Registry","ASPERA","Inclusion Criteria:\n\n* Age ≥18 years at the time of the index ischemic stroke.\n* Confirmed diagnosis of ischemic stroke according to the World Health Organization (WHO) definition.\n* Availability of at least one neuroimaging exam (either a non-contrast computed tomography \\[NCCT\\] or magnetic resonance imaging \\[MRI\\] of the brain) demonstrating one or more ischemic lesions consistent with patient symptoms.\n* Ongoing oral anticoagulation at the time of the index ischemic stroke, defined as the last intake within 48 hours prior to stroke symptom onset for patients on direct oral anticoagulants (DOACs), or an international normalized ratio (INR) of ≥1.5 in patients on vitamin K antagonists (VKAs), regardless of the time elapsed between the last intake and stroke symptom onset.\n* Prior diagnosis of AF or other cardioembolic arrhythmias.\n\nExclusion Criteria:\n\n* Symptoms not indicative of acute stroke (i.e., syncope, tonic or clonic activity, dizziness alone, confusion and amnesia alone, chronic or subacute development of focal neurological deficit).\n* Ongoing parenteral (intravenous or subcutaneous) anticoagulation at the time of the index event, including bridging with heparin in patients initiating VKA.",{"count":111,"type":20},200,"5 Years","The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or other cardioembolic arrhythmias and to characterize short and long-term outcomes associated with different secondary prevention strategies to prevent stroke recurrences. The ASPERA study is a multicenter, observational, both retrospective and prospective real-world study involving acute ischemic stroke patients occurring on oral anticoagulation. The study will encompass a retrospective (ASPERA-R) and prospective (ASPERA-P) data collection. Patient will be recruited consecutively at different emergency services and stroke units worldwide. University of L'Aquila (UnivAQ) will be in charge of study coordination, data analysis and management. The duration of ASPERA-R will be of 5-year from the study initiation of the study. Participating centers will be given a 6-month timeframe to enter retrospective data, commencing from the date of study approval.\n\nASPERA-P duration will be of 2 years of enrollment from the study approval and follow-up of 5 years. (study conclusion after 7 years of approval). Inclusion criteria will be: 1.Confirmed diagnosis of ischemic stroke. 2. Availability of at least one neuroimaging exam positive for ischemic lesion(s) consistent with patient symptoms. 3. Ongoing oral anticoagulation at the time of the index ischemic stroke. 4. Prior diagnosis of atrial fibrillation or other cardioembolic arrhythmias. 5. Written informed consent provided by the patient himself or by proxy. Patients with Symptoms not indicative of acute stroke, ongoing intravenous or subcutaneous anticoagulation at the time of stroke will be excluded. ASPERA-R: characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. The primary outcome will be: ASPERA-R : characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. ASPERA-P: risk of ischemic stroke recurrence of ischemic stroke cases occurring on oral anticoagulants across different secondary preventive strategies (i.e., maintaining the same type of oral anticoagulation versus switching to a different secondary prevention strategy) at 90 days, 1 and 5 years after the index stroke. Additionally, the study will aim to investigate the risk of safety events (hemorrhagic transformation, intracranial hemorrhage, other major bleeding events, any bleeding events, death due to any cause), risk of other major ischemic events (transient ischemic attack, myocardial infarction, death due to vascular causes) at each follow-up and to identify demographic, clinical and neuroimaging features of ischemic stroke recurrences.",[115,116,117,118,119],"Ischemic Stroke","Oral Anticoagulation","Atrial Fibrillation (AF)","Outcome Assessment","Clinical Presentations",[121,122,123,124,125,126,127,128,129],"Ischemic stroke","Oral anticoagulation","Atrial fibrillation","Direct oral anticoagulants","Vitamin k antagonists","Outcomes","Prognosis","Clinical characteristics","Secondary prevention","2025-02-17",{"date":132,"type":42},"2025-02-20",{"date":134,"type":42},"2025-02-12",{"date":136,"type":20},"2031-02-12",{"name":48,"class":49},47,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":149,"conditions":150,"keywords":154,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100501973","point-of-care-low-field-mri-in-acute-stroke-100501973","NCT05816213","Point-of-care Low-field MRI in Acute Stroke","Point-of-care Low-field Magnetic Resonance Imaging in Acute Stroke (POCS) Study","POCS","Inclusion Criteria:\n\n1. symptoms suggestive of acute stroke (acute onset of a focal neurological deficit which can be referred to the involvement of a specific CNS region);\n2. stroke onset \\\u003C24 h since when the patient was last known healthy;\n3. written informed consent provided by the patient himself or by proxy (for unconscious patients, cognitively impaired or aphasic).\n\nExclusion Criteria:\n\n1. symptoms not indicative of acute stroke (e.g. syncope, tonic or clonic activity, dizziness or wooziness alone, confusion and amnesia alone, subacute or chronic development of a focal neurological deficit);\n2. inability to undergo LF-MRI due to critically impaired vital functions (e.g. hemodynamically unstable patients, need of immediate life-saving maneuvers);\n3. implanted ferromagnetic devices potentially interfering with LF-MRI (e.g. cochlear implants);\n4. impossibility to achieve written informed consent.",{"count":148,"type":20},300,"Consecutive patients accessing the emergency department with suspected stroke dispatch will be recruited at 3 study units: 1) ASL Abruzzo 1, hospitals of L'Aquila and Avezzano; 2) ASL Abruzzo 2, hospital of Chieti; 3) IRCCS Humanitas Research Hospital of Milan. Anonymized clinical and low-field (LF) MRI data as well as conventional neuroimaging data will be independently assessed by external units (Università Politecnica delle Marche and Policlinico di Messina, respectively). Both units will independently adjudicate the best treatment option, while the latter will also provide historical MRI data of stroke patients to develop artificial intelligence algorithms facilitating LF-MRI images interpretation (Libera Università di Bolzano). Agreement with conventional neuroimaging will be evaluated at different time points (hyperacute, acute -24 h, subacute -72 h, discharge, chronic -4 weeks). Further investigations will include feasibility study to develop an ambulance (mobile stroke unit) equipped with LF-MRI and cost-effectiveness analysis of LF-MRI. This trial will provide necessary data to validate the use of LF-MRI in the acute stroke care.",[151,115,152,153],"Stroke","Hemorrhagic Stroke","Magnetic Resonance Imaging",[151,155,156,157],"Diagnosis","Low-field MRI","Stroke treatment","2024-12-04",{"date":160,"type":42},"2024-12-09",{"date":162,"type":20},"2025-02-01",{"date":164,"type":20},"2026-11-01",{"name":48,"class":49},4,""]